Compare EKSO & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EKSO | TCRT |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.1M |
| IPO Year | N/A | N/A |
| Metric | EKSO | TCRT |
|---|---|---|
| Price | $4.67 | $4.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 315.9K | 65.9K |
| Earning Date | 10-28-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,749,000.00 | $6,000.00 |
| Revenue This Year | N/A | $5,680,500.00 |
| Revenue Next Year | $54.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.73 | $1.31 |
| 52 Week High | $14.97 | $6.20 |
| Indicator | EKSO | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 69.16 |
| Support Level | $3.50 | $3.23 |
| Resistance Level | $4.93 | $3.52 |
| Average True Range (ATR) | 0.40 | 0.36 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 81.25 | 85.37 |
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.